Increased level of HMGB1 in patients with psoriasis

[Fred]

This small study looked at the levels of High mobility group box 1 protein (HMGB1) in patients with psoriasis. It showed an increased level of HMGB1 in patients with psoriasis and suggests that levels are significantly increased with disease progression and are down regulated after standard therapies.

Quote:

---

Background:
Psoriasis vulgaris (PV) is an autoimmune-related chronic inflammatory disease, which appears mostly in skin, but also affects the vascular and metabolic system. The incidence of PV is 2–3% in the general population and there is still no possibility to cure. Trigger factors have been identified to initiate and maintain inflammation in the skin, which is characterized by Th1-, Th17- and Th22- cells.

Objective:
We hypothesize that the damage-associated molecular pattern (DAMP) molecule high mobility group box 1 (HMGB1) plays a role in the pathogenesis of PV. HMGB1 is a DNA-binding protein located in the nucleus, which acquires cytokine-like properties once released from the cell upon necrotic cell death or actively secreted by immune cells in inflammation and cancer.

Methods:
We recruited 90 psoriatic patients under and without therapy with mild, intermediate and severe progression of disease, defined by the Psoriasis Area Severity Index. Serum levels of HMGB1 in patients with PV were detected by enzyme-linked immunosorbent assay (ELISA).

Results:
Our results show an increased level of HMGB1 in the sera of patients with PV in comparison to healthy donors. Furthermore, our analyses reveal that HMGB1 levels are significantly increased with disease progression and are downregulated after standard therapies for PV have been conducted.

Conclusion:
Our data provide insights into a possible role of HMGB1 for inflammation in PV.

Source: onlinelibrary.wiley.com

*Early view funding unknown.